Altuvoct
What Altuvoct is used for
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Altuvoct can be used for all age groups.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Altuvoct
- Active substance
- efanesoctocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- Swedish Orphan Biovitrum AB (publ)
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Altuvoct used for?
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Altuvoct can be used for all age groups.
What is the active substance in Altuvoct?
Altuvoct contains efanesoctocog alfa.
Who makes Altuvoct?
The EU marketing authorisation holder is Swedish Orphan Biovitrum AB (publ).
Is Altuvoct an orphan medicine?
Yes. Altuvoct is designated an orphan medicine in the EU, for a rare disease (Hemophilia A).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU